About
ProPhet is an AI-driven company transforming small molecule drug discovery, with a focus on proteins that are hard to target using competitive methods. The company develops advanced technology to identify potential therapeutics for these challenging targets, addressing a critical need in the pharmaceutical industry.
Its innovative approach leverages artificial intelligence and machine learning to speed up and enhance the early stages of drug discovery. By predicting protein dynamics and how they interact with drug candidates, ProPhet can rapidly identify promising molecules. This allows to tackle proteins with limited structural information, opening new possibilities for treating diseases previously considered “undruggable.”
ProPhet stands out by combining speed, precision, and scientific rigor. Its AI platform evaluates vast libraries of small molecules, offering faster, more efficient, and cost-effective solutions compared to both traditional and other AI-based methods. By doing so, it helps pharmaceutical companies and researchers explore a broader range of treatments with more accuracy, backed by scientifically interpretable results.
Its vision is to revolutionize drug discovery, making it faster and more accessible. ProPhet aims to deliver better solutions to help meet unmet medical needs and improve patient outcomes.
Funding history · 1 round · $1.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When was ProPhet founded?
- ProPhet was founded in July 2024.
- What is ProPhet's primary focus in drug discovery?
- ProPhet focuses on transforming small molecule drug discovery using AI, specifically targeting proteins that are difficult to address with competitive methods.
- How many employees does ProPhet currently have?
- ProPhet currently has 8 employees.
- What was ProPhet's first funding round?
- ProPhet secured a Pre-Seed funding round in July 2024.
- Which investors participated in ProPhet's Pre-Seed round?
- The Pre-Seed round included investments from Merck, AION Labs, AstraZeneca, and Israel Biotech Fund.
- What is ProPhet's current funding stage?
- ProPhet is currently in the Pre-Seed funding stage.
- Where is ProPhet's headquarters located?
- ProPhet's headquarters is located in Rehovot, Israel.
- What technologies does ProPhet leverage in its drug discovery platform?
- ProPhet leverages Artificial Intelligence, Machine Learning, and Deep Learning in its platform to predict protein dynamics and interactions with drug candidates.
- Who are the founders of ProPhet?
- The founders of ProPhet are Tom Shani, Avital Sharir-Ivry, and Amitai Mordechai.